ML model cuts drug synthesis runs 10x

This is what low-data ML looks like when it actually works — a model trained on four papers outperforming brute-force experimental search is a genuine result worth noting.

• –Most ML models demand enormous training sets; this workflow achieves reliable predictions from a handful of published reactions, suggesting the chemical structure encoding strategy is unusually data-efficient
• –Asymmetric reactions are a core bottleneck in pharma — getting "handed" molecules right is critical for drug safety and efficacy, making this a high-value target for automation
• –The 5-10 vs. 50-60 experiment reduction isn't just cost savings; it compresses drug candidate optimization timelines that currently bottleneck clinical trial progression
• –Built by the Sigman and Doyle labs, both leaders in data-driven chemistry — this has pedigree, not just hype
• –Published in Nature (Feb 11, 2026), lending significant credibility; watch for follow-on tools or commercial spinouts from this group